CORCEPT THERAPEUTICS INC Logo

CORCEPT THERAPEUTICS INC

Develops and commercializes cortisol-modulating drugs for severe disorders like Cushing's syndrome.

CORT | US

Overview

Corporate Details

ISIN(s):
US2183521028
LEI:
Country:
United States of America
Address:
101 REDWOOD SHORES PARKWAY, 94065 REDWOOD CITY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Corcept Therapeutics is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of medications that modulate the effects of cortisol. The company's scientific approach centers on regulating cortisol activity at the glucocorticoid receptor (GR) to develop novel treatments for severe disorders. Its lead product, Korlym®, is approved for treating hyperglycemia associated with endogenous Cushing's syndrome. Corcept is advancing a broad clinical pipeline of selective cortisol modulators for a range of diseases across key therapeutic areas, including endocrinology, oncology, metabolism, and neurology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CORCEPT THERAPEUTICS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CORCEPT THERAPEUTICS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CORCEPT THERAPEUTICS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea
475830
OSR Holdings, Inc. Logo
Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.
United States of America
OSRH
OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America
OSTX
Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan
4578
Outlook Therapeutics, Inc. Logo
Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.
United States of America
OTLK
Ovid Therapeutics Inc. Logo
Developing targeted small molecule therapies for rare neurological diseases and epilepsies.
United States of America
OVID
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland
OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom
OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom
OCTHF
Pacira BioSciences, Inc. Logo
Advancing non-opioid therapies for postsurgical, chronic, and musculoskeletal pain.
United States of America
PCRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.